tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ATHE Stock Latest News

Alterity Therapeutics Options Expire Unexercised
Company AnnouncementsAlterity Therapeutics Options Expire Unexercised
17d ago
6K
ATHE
Alterity Therapeutics Options Expire Unexercised
PremiumCompany Announcements
Alterity Therapeutics Options Expire Unexercised
2M ago
6K
ATHE
Alterity Therapeutics reports cash balance of A$12.6M as of June 30
PremiumThe Fly
Alterity Therapeutics reports cash balance of A$12.6M as of June 30
2M ago
ATHE
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
PremiumPress Releases
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
2M ago
ATHE
Alterity Therapeutics to Present at MST Financial Webinar
PremiumPress Releases
Alterity Therapeutics to Present at MST Financial Webinar
2M ago
ATHE
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
2M ago
ADVM
ALLO
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Premium
Press Releases
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
2M ago
ATHE
Alterity Therapeutics reports interim data from ATH434-202 Phase 2 trial in MSA
Premium
The Fly
Alterity Therapeutics reports interim data from ATH434-202 Phase 2 trial in MSA
2M ago
ATHE
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
PremiumPress Releases
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
2M ago
ATHE
Alterity Therapeutics Issues New Employee Options
PremiumCompany Announcements
Alterity Therapeutics Issues New Employee Options
3M ago
6K
ATHE
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
PremiumPress Releases
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
3M ago
ATHE
Alterity Therapeutics Unveils Critical Study Data
PremiumCompany Announcements
Alterity Therapeutics Unveils Critical Study Data
4M ago
6K
ATHE
Alterity Therapeutics Announces Option Cessation
PremiumCompany AnnouncementsAlterity Therapeutics Announces Option Cessation
4M ago
6K
ATHE
Alterity’s ATH434 Advances in Phase 2 MSA Trial
Premium
Company Announcements
Alterity’s ATH434 Advances in Phase 2 MSA Trial
4M ago
6K
ATHE
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
Premium
The Fly
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
4M ago
ATHE
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
PremiumPress Releases
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
4M ago
ATHE
Alterity Therapeutics Gains Momentum in Q3
PremiumCompany Announcements
Alterity Therapeutics Gains Momentum in Q3
5M ago
6K
ATHE
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
PremiumPress Releases
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
5M ago
ATHE
Alterity Therapeutics reports cash position of A$18.3M as of March 31
PremiumThe Fly
Alterity Therapeutics reports cash position of A$18.3M as of March 31
5M ago
ATHE
Alterity Therapeutics presents new data demonstrating potential of ATH434
PremiumThe FlyAlterity Therapeutics presents new data demonstrating potential of ATH434
5M ago
ATHE
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Premium
Press Releases
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
5M ago
ATHE
Alterity Therapeutics’ ATH434 Shows Treatment Promise
Premium
Company Announcements
Alterity Therapeutics’ ATH434 Shows Treatment Promise
5M ago
6K
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >